BioBusiness Winter School 2022

MEET YOUR MATCH

Participants in the BioBusiness Winter School get the opportunity to learn more about specific positions and organisations within the industry during the 45-minute Meet your Match sessions. We have selected the following professionals for this years' Meet your Match:

Liesbeth Ceelen

Liesbeth Ceelen holds a master degree in veterinary medicine and of laboratory animal sciences. After earning her PhD in veterinary sciences, she started her career at J&J in 2007. Next, she was working in different start-up and scale-up companies in the biotech and healthcare field where she took on various roles (operational, quality, projectmanagement, scientific, sales and business development). Since 2019, Liesbeth’s main role, as CEO, is to make BioLizard the go to bioinformatics consultancy company in Europe and the US. She is also scientific advisory board member for the Novalis Biotech Incubation Fund.

About BioLizard

BioLizard, located in Ghent, leverages its expertise in bioinformatics, biostatistics, machine learning, artificial intelligence and data mining to solve the most challenging questions in biology and deliver solutions to clients. By combining expertise from diverse backgrounds, BioLizard provides a complete solution to its client - from data analysis to the system integration and the development of an AI-aided interpretation system. The company was founded by Novalis Biotech Incubation. For more information visit www.lizard.bio.

Franziska Mortensen

Franziska Mortensen is working as scientist in a biotech company (Merus NV). She gets a lot of energy from her job and is happy to have taken this path. It all started in Germany where she studied ‘Applied Natural Sciences’. Her curiosity pushed her to continue with research for a while and she ultimately received her PhD in protein biochemistry in 2015. She moved to the Netherlands for a Postdoc position and realized after a while that she wants to continue with research and development outside of academia. After some tough months of applications and interviews she found the position that was made for her. Her work as scientist demands a lot of flexibility and growth, and that makes it such an exciting career path.

About Merus

Merus NV (Merus) is a clinical-stage biotechnology company developing multi-specific antibodies to address unmet needs of patients with various types of cancer. The therapeutic candidates are designed to engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways. The clinical pipeline is composed of several bispecific antibody candidates, with several other candidates in pre-clinical development. Merus has been a publicly traded company on the Nasdaq since 2016. Merus’ headquarters are located in Utrecht, the Netherlands, with a subsidiary, Merus US Inc. located in Cambridge (MA) in the USA and collaborators, licensees and clinical trial sites located around the world.

Gemma Moiset

Dr. Moiset is Group Leader at Charles River Laboratories in Leiden, The Netherlands. Her research focuses on in vitro efficacy and toxicity testing of novel drug therapies in human primary cell-based models. Formerly, Dr. Moiset worked in Biotech contributing to the development of monoclonal antibodies against cancer. Prior to that, she was a post-doctoral fellow at the Netherlands Cancer Institute. Dr. Moiset has a combined background in immunology, cellular biology and medicinal chemistry. She holds a PhD in Life Sciences from the University of Groningen and Zernike Institute for Advanced Materials.

About Charles River Laboratories

Charles River is an early-stage CRO with a diverse portfolio of discovery and safety assessment services to support clients from target identification through preclinical development. We also provide products and services to support clinical laboratory testing needs and manufacturing activities. We are passionate about our role in improving the quality of people’s lives and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

Laura Restrepo

Laura Restrepo is a strategy consultant at Vintura, a boutique consultancy firm specialized in healthcare and lifesciences. As a consultant, she works in a wide range of topics in the pharmaceutical industry, including Value-Based Healthcare (VBHC), digital health and self-care. She was trained as a Biomedical Engineer and worked in the fields of bio- and nano- technology during her PhD in TU Delft. She has an interest in disruptive and cutting-edge technologies and aims to help bring these technologies closer to patients.

About Vintura

Vintura is a leading strategy & organisation consultancy specialised in healthcare and life sciences, founded in 2000 in the Netherlands. We apply our extensive expertise and experience to support healthcare providers, payers and pharmaceuticals and medical devices companies to bring about ongoing improvement based on a clear vision and solid strategy. Vintura operates both on an international and local level, with 30+ dedicated professionals working in our offices across Europe (the Netherlands, United Kingdom, Italy and Germany).We work with our clients to arrive at smart and effective solutions. Our mission is ‘creating meaningful impact in healthcare together’. We do so based on our core values: being ambitious and brave in finding the best solutions whilst being emphatic and sincere to create optimal commitment.

Gideon Bevelander

Gideon Bevelander is a Medical Research Liaison at Argenx, responsible for the Netherlands and Nordics. Formerly, Gideon worked for J&J Innovation as part of the external innovation partnering team responsible for external engagement and innovation sourcing mainly for the Benelux. Prior to this role, Gideon spent 10 years at Janssen, working within the Immunology Therapeutic Area in different medical affairs positions educating, communicating scientific information and working on multiple projects with a variety of stakeholders. Gideon holds a master’s degree in biology and earned his PhD in animal physiology.

About agenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only FDA approved neonatal Fc receptor blocker, VYVGART (efgartigimod alfa-fcab) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

Rajiv Vaid Basaiwmoit

Dr. Rajiv Vaid Basaiawmoit, Ph.D., MBA, is the Head of Sci-Tech Innovation & Entrepreneurship at Aarhus University, Denmark. He is an award-winning Entrepreneurship Educator and works at the intersection between innovation, entrepreneurship, interdisciplinary-collaboration and gamification. He designs and embeds Entrepreneurship into curricular education. During BioBusines Winter School, he will introduce the subject of patents using a gamification tool.

Advanced Patent Game

Would you like to learn more about patenting in Life Sciences after the patent escape room on Wednesday? Then join the Advanced Patent Game where you can further enhance your knowledge and skills on patenting in Life Sciences! During this session you will work together in groups to complete a more advanced IP challenge based on real life cases.